The visceral shelf, deep and specific.
The two molecules in this lane share little except their target depth: Larazotide acts at the tight junctions of the intestinal epithelium, and Tesamorelin acts on hepatic visceral fat through the GH/IGF-1 axis. Both are research compounds with strong human data and very specific use profiles.
Larazotide 5 mg
Zonulin antagonist with strong celiac and intestinal-barrier research record. Orally bioavailable — unusual for a peptide.
Tesamorelin 5 mg
GHRH analog with sharper visceral-adipose signal than the broader GH stack. Established human data on visceral fat reduction.
Two research questions, two very different molecules.
This lane is narrower than the others. Both molecules are highly specific to a particular tissue or system, and neither is a generalist research tool. If your endpoint is broad, you're in a different lane.
Larazotide is an 8-amino-acid peptide that modulates zonulin-driven tight-junction permeability in the small intestine. The published research is dense on celiac-disease endpoints, intestinal barrier integrity, and tight-junction dynamics — and it's orally bioavailable, which is rare for peptides this size.
Tesamorelin is a GHRH analog with FDA approval for HIV-associated lipodystrophy and a substantial research record on visceral adipose reduction. It works through the GH/IGF-1 axis but with a sharper visceral-specific signal than the broader GH stack in the Performance lane.
Below: the two products, the stacks patients run alongside, and a decision tree.
Three questions, one starting molecule.
Studying intestinal barrier?
Larazotide's tight-junction mechanism is the cleanest signal in the literature for zonulin-driven barrier endpoints. Oral bioavailability also makes the protocol simpler than most peptide research.
Pick → Larazotide
Studying visceral adipose?
Tesamorelin's GHRH analog activity produces a sharp, visceral-specific signal — distinct from the broader GH stack in the Performance lane, which has more peripheral effects. · Pick · Tesamorelin
Pick → Tesamorelin
Both, with GLP-1?
Visceral-axis research often layers Tesamorelin on top of a GLP-1 protocol to study additive effects. Larazotide is independent and pairs cleanly with most other lanes.
Pick → Either, layered
Stacks patients run alongside.
All 9 stacks →
Patient questions, answered.
Six things we get asked most about the gut & metabolic lane. For dosing math, use the calculator. For purity records, every PDP has the full COA archive.
What does "tight-junction modulator" actually mean?
Tight junctions are the protein complexes that regulate what crosses the intestinal epithelium. Zonulin is the signaling molecule that opens them; Larazotide is a zonulin antagonist that helps maintain barrier integrity.
Is Larazotide really orally bioavailable?
Yes — it's one of the few peptides this size that survives gastric pH and absorbs adequately. It's why most published protocols use oral dosing.
How is Tesamorelin different from the Ipa/CJC blend?
Both work on the GH axis, but Tesamorelin's signal is sharper for visceral adipose specifically, while Ipa/CJC produces a broader GH pulse with more peripheral effects. Different research endpoints.
Can I run Tesamorelin alongside a GLP-1?
Several published protocols layer them to study additive visceral effects. The mechanisms don't compete and the half-lives are very different. We don't make clinical recommendations.
What's the protocol length on these?
Most published Larazotide research is 4–12 weeks. Tesamorelin visceral-fat protocols read out around 6 months. Plan accordingly.
What's the COA cadence on this lane?
Every lot, no exceptions. ISO-17025 third-party HPLC + mass spec, plus endotoxin, plus residual solvents. Each PDP shows the lot number you'll receive and links to the matching COA.
Layer the visceral lane with GLP-1?
Tesamorelin + Tirzepatide is a researcher-built combination for additive visceral-adipose work. See the full Stacks page for variations.